Introduction
Dysregulation of both insulin-like growth factor-1 receptor (IGF-1R) signaling and the phosphatidylinositol 3-kinase (PI3K)/ AKT/ mammalian target of rapamycin (mTOR) signaling pathways are biologically important in a variety of cancers, including many subtypes of sarcomas (1, 2, 3) . IGF-1R, a trans-membrane tyrosine kinase, is widely expressed on normal human tissue and plays important role in growth, development, and angiogenesis. Preclinical studies have shown that fibroblasts lacking IGF-1R cannot be transformed by most oncogenes but this susceptibility is restored if IGF-1R expression is reinstituted (4, 5) . Consequent to binding of IGF-1 or IGF-2 ligands, IGF-1R signaling activates the PI-3-kinase/AKT/mTOR as well as the Ras/Raf/MAPK signal transduction cascades. Interruption of these signals results in anti-proliferative effects seen in both malignant cell cultures and tumor xenograft models (6, 7) . Several inhibitory monoclonal antibodies targeting IGF-1R have demonstrated clinical benefit in certain sarcoma subsets, most notably Ewing sarcomas, and remain in active clinical development (8, 9, 10) .
The mammalian target of rapamycin (mTOR) is a serine/theorine tyrosine kinase which functions as a key regulatory protein in normal cell growth, development, metabolism, as well as angiogenic pathways. It is downstream of PI3K-AKT signaling pathway and can be activated in response to mitogens, nutrients and growth factor receptor signals, thereby playing crucial roles in the control of normal cellular growth and function as well as cancer cell proliferation and angiogenesis. (11) . Many mechanisms can result in physiologic signaling, feedback loops activated by mTOR signaling attenuate signals from IGF-1R; blockade of mTOR signaling by agents such as rapalogues leads to loss of feedback inhibition with enhanced signaling through IGF-1R and other growth factors, with consequent up-regulation of p-AKT levels. This loss of normal feedback inhibition by mTOR blockade could potentially result in increased cell survival and resistance to cancer therapy (13, 14, 15, 16) . This unintended consequence may in part explain the limited efficacy and transient benefits usually noted with single agent mTOR inhibition.
Preclinical data have suggested that combined blockade of IGF-1R and mTOR may ameliorate this problem and lead to enhanced anti-neoplastic efficacy against sarcomas and other solid tumors. (14, 17) Both IGF-1R and mTOR inhibitors have been developed through phase II and phase III trials respectively as single agents, and the safety and tolerability profiles for these agents indicate no major overlapping toxicities.
Based on this scientific rationale, we have designed and conducted a phase I trial combining a fully human monoclonal antibody with inhibitory activity against IGF-1R signaling, figitumumab (previously known as CP-751,871) with the oral small molecule rapalogue mTOR inhibitor, everolimus (previously known as RAD001) in patients with advanced sarcomas and other solid tumors.
Methods

Patients and Study Design
The study was a single center, 
Procedures
This study employed a dose de-escalation design. Since no overlapping dose limiting toxicities were expected from prior studies of single-agent everolimus and figitumumab, the initial dose level combined the recommended full dose of figitumumab (20 mg/kg IV repeated every 21 days) with the standard approved dose of everolimus (10 mg orally once daily) (18, 19, 20) . Study participants were enrolled in a standard 3+3 cohort design. Drug doses would be de-escalated in subsequent cohorts if DLT was observed in either >2 of the first 3 patients enrolled or >2 of the first 6 patients enrolled. Fifteen additional patients were to be enrolled at the recommended phase II dose (RP2D). This cohort size was selected to provide an estimation of toxicity rates with a 90% confidence interval no wider than +/-23%. Study participants were allowed to continue combined study drug administration as long as there were no unacceptably severe adverse effects and there was no evidence of disease progression. 
Statistical Analysis
Descriptive statistics were used to characterize patients at study entry. 90% two-sided exact binomial confidence intervals were computed for the partial response rate, stable disease rate, progressive disease rate, and severe toxicity rate. The area under the plasma concentration-time curve in cycle 1 (AUC 0-d22 ) was calculated for figitumumab using the trapezoidal method as implemented in SAS. The terminal disposition half-life was not estimated due to lack of data. All statistical analyses were done with SAS (version 9.2).
Role of funding source
This study was designed and written by the investigators with limited support from Novartis and Pfizer in providing study drugs, pharmacokinetic assessment and nonstandard investigations as part of screening procedures. The investigators alone were responsible for data collection and analysis of the raw data. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
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Twenty (21%) of the 96 cycles of study drug administered were delayed due to toxicity.
The most common reason for dose delay was platelet count less than 100,000 on the planned d1 which occurred in 6 cycles (6% patients enrolled on study, 2 patients (9.5%), both in the expansion cohort, were removed from study due to toxicity during cycle 1. staging scan. Eleven (52%) patients were on study drug for more than 100 days ( Figure   3 ).
Preliminary Evidence of Antitumor Activity
Pharmacokinetic profiling of study drugs
Pharmacokinetic studies were performed at limited time points in this study. Blood samples of everolimus were available in all 21 patients on day 1 and 8 of cycle 1, with 3 missing on cycle 1 day 15 and cycle 2 day 1. Blood samples of figitumumab were available at 1 hour after the end of infusion on cycle 1 day 1 in 20 of the 21 patients, with 1, 2 and 2 missing on cycle 1 day1, cycle 1 day 15 and cycle 2 day 1, respectively.
There was no evident pharmacologic interaction between study drugs, and drug levels were comparable to levels expected based on single-agent trial reports. Everolimus steady-state plasma level (trough) at day 15 was 10.3 ± 6.5 ng/mL (n=18). cancer, and preclinical models suggest synergistic antitumor activity with combined inhibition of these pathways (14, 17) .
Our study demonstrated that it is safe to combine figitumumab and everolimus at full doses recommended for each agent individually. Two other recently reported phase I studies evaluating combined mTOR and IGF-R inhibition using different combinations of agents have corroborated that this combination blockade is feasible in patients ( 22, 23) .
The toxicities encountered in the current combination phase I study were similar to those reported with each drug individually, and no new safety concerns were detected ( 9, 15, 18, 19, 24) . Prolonged study drug administration was associated with need for dose modification in some patients. The toxicities observed were consistent with what is expected from prolonged administration of full dose everolimus and dose reduction of everolimus successfully managed these toxicities. Although concerns regarding cardiac toxicities have been raised with IGF1R antibodies when combined with cytoxic chemotherapy, we did not observe any treatment related cardiac events. Due to the theoretically worse induction of hyperglycemia with these two agents, close monitoring of fasting blood glucose was performed. In a large phase III study, treatment-emergent hyperglycemia was reported in 50% of everolimus treated-patients, of which approximately a third of patients had grade 3 hyperglycemia (20) . Similarly in single agent figitumumab dose escalation studies, hyperglycemia was a common adverse event (19) . In the current study we observed asymptomatic hyperglycemia in 13 patients 
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Copyright © 2010 American Association for Cancer Research patient. Mucositis was the predominant adverse event in our study; 33% and 14% experienced grade 2 and 3 mucositis respectively and is consistent with the known side effects of mTOR inhibitors. We found this toxicity to be manageable with temporary dose interruptions, local therapy and, in some instances, dose reduction of everolimus.
Although thrombocytopenia was the most commonly observed reason for treatment delay, likely related to both figitumumab and everolimus, thrombocytopenia observed was grade 1 or grade 2, did not require dose modification and typically was not a recurring toxicity for individual patients.
A number of patients on study experienced prolonged disease stability, including patients with metastatic solitary fibrous tumor, Ewing's sarcoma, high grade spindle cell sarcoma, osteosarcoma, adrenal cortical carcinoma and leiomyosarcoma, suggesting that the combination may be impacting tumor proliferation despite the lack of tumor shrinkage sufficient to reach formal objective response. Previous studies have implicated either the IGF-1R, or PI3K-AKT-mTOR pathway as relevant to these histologies, suggesting that inhibition of these target pathways may lead to disease control (8, 9, 10, 25, 26, 27, 28) . The most pronounced anti-tumor signal we observed in A limitation of the current study is the lack of biomarkers to assess the status of the IGF-R, mTOR-PI3K_AKT pathway in the patient population studied. As the primary aim of this investigation was to assess the safety of this novel combination, these investigations were not included, however, further assessment of tumor efficacy and predictors of response should be included in future studies.
In conclusion, our results show that figitumumab and everolimus can be administered in 
